Streetbeat News

Products Services

META

Meta has been upgraded to 'Strong Buy' with a fair value of $699 per share, driven by the potential TikTok ban and the advanced Llama 3.3 AI model. A TikTok ban could boost Meta's user growth by over 2.5%, while the Llama 3.3 model enhances its AI capabilities.

Portfolio Pulse from

December 09, 2024 | 2:30 am

LRE

Lead Real Estate Co., Ltd. (Nasdaq: LRE) is launching a new extended-stay apartment hotel, ENT TERRACE GINZA Premium, in Tokyo on December 16, 2024. This expansion into the hospitality sector could impact LRE's business and stock performance.

Portfolio Pulse from

December 09, 2024 | 2:15 am

NEE

NextEra Energy is poised to benefit from increasing power demand due to AI, data centers, and industrial electrification. With a 29-year history of dividend increases and a target of 10% annual growth through 2026, it remains attractive for income investors. Despite its premium valuation, its operational efficiency and renewable energy focus offer a competitive advantage, with potential upside if interest rates decrease.

Portfolio Pulse from

December 09, 2024 | 2:15 am

MTSI

Lou Basenese, MDB Capital Holdings President, recommends MACOM Technology Solutions (MTSI) as a top pick in the semiconductor industry due to its strong momentum and valuable IP portfolio.

Portfolio Pulse from

December 09, 2024 | 1:45 am

QDPL

The Pacer Metaurus US Large Cap Dividend Multiplier 400 ETF (QDPL) offers a 5% dividend yield, providing a reliable income stream for investors seeking growth and income. It serves as an alternative to the 4% rule for retirement, which requires selling shares to fund retirement.

Portfolio Pulse from

December 08, 2024 | 11:00 pm

ABBV

AbbVie released a report highlighting the emotional impact of chronic lymphocytic leukemia (CLL) on underrepresented patients, revealing that Black, Hispanic, and Asian patients experience more negative emotional effects. CLL affects over 200,000 people in the U.S.

Portfolio Pulse from

December 08, 2024 | 8:15 pm

BEAM

Beam Therapeutics presented promising non-human primate data at the ASH Annual Meeting, showcasing a new non-genotoxic, antibody-based conditioning approach for treating sickle cell disease. The data demonstrated successful long-term engraftment of base-edited hematopoietic stem cells and robust levels of Hemoglobin F.

Portfolio Pulse from

December 08, 2024 | 7:00 pm

VRTX

Vertex Pharmaceuticals announced positive long-term data for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, at the ASH Annual Meeting. The data from global clinical trials show promising results for patients with severe sickle cell disease and transfusion-dependent beta thalassemia.

Portfolio Pulse from

December 08, 2024 | 6:15 pm

AGIO

Agios Pharmaceuticals announced positive results from its Phase 3 ENERGIZE-T study of Mitapivat, achieving primary and key secondary endpoints in adult patients with transfusion-dependent alpha- or beta-thalassemia. The company also provided a regulatory update on Mitapivat.

Portfolio Pulse from

December 08, 2024 | 6:00 pm

JNJ

Johnson & Johnson announced promising results for TECVAYLI® (teclistamab-cqyv) as a frontline combination therapy for newly diagnosed multiple myeloma. The studies showed 100% MRD negativity in patients, indicating strong efficacy and a tolerable safety profile.

Portfolio Pulse from

December 08, 2024 | 5:45 pm